FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Antibodies topics
Antibodies
Recombinant
Nucleic Acid
Nucleic Acids
Polypeptide
Therapeutics
Immunoglobulin
Immunoglobulins
Monoclonal
Radiation Therapy
Desmoplastic
Hypertension
Hypertensive
Immunotherapy
Photodynamic Therapy

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Antibodies patents



      
           
This page is updated frequently with new Antibodies-related patent applications. Subscribe to the Antibodies RSS feed to automatically get the update: related Antibodies RSS feeds. RSS updates for this page: Antibodies RSS RSS


Date/App# patent app List of recent Antibodies-related patents
12/18/14
20140373195
 Axmi345 delta-endotoxin gene and methods for its use patent thumbnailnew patent Axmi345 delta-endotoxin gene and methods for its use
Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a toxin polypeptide are provided.
12/18/14
20140371476
 Oil degumming methods patent thumbnailnew patent Oil degumming methods
In alternative embodiments, the invention provides phosphatidylinositol-specific phospholipase c (pi-plc) enzymes, nucleic acids encoding them, antibodies that bind specifically to them, and methods for making and using them. Industrial methods and products comprising use of these phospholipases are also provided.
12/18/14
20140371430
 Antibodies specific to pyroglutamated abeta patent thumbnailnew patent Antibodies specific to pyroglutamated abeta
The present disclosure relates to antibodies specific for pyroglutamated aβ, as well as their use in the treatment of alzheimer's disease and as use in diagnostic methods or as diagnostic imaging ligands further, is provided pyroglutamated n-terminal fragments of murine or human aβ to generate antibodies and for use m therapeutic purposes. .
12/18/14
20140371142
 Myonectin (ctrp15), compositions comprising same, and methods of use patent thumbnailnew patent Myonectin (ctrp15), compositions comprising same, and methods of use
Disclosed is the novel myokine known as myonectin (ctrp15), an isolated nucleic acid encoding the myonectin (ctrp15) gene, and the amino acid sequence encoding the myonectin (ctrp15) protein. Methods of isolation of the nucleic acid, protein, polypeptides and methods of making antibodies to the myonectin (ctrp15) protein are provided.
12/18/14
20140371101
 Parp substrates and biomarkers patent thumbnailnew patent Parp substrates and biomarkers
Parylated proteins are enriched by treating cell lysates comprising parylated proteins and dna/rna with an endonuclease that cleaves the dna/rna but not the par; and separating the parylated proteins from the cleaved dna/rna. Parylation sites are labeled by eluting parylated proteins from a par-affinity substrate with a nucleophilic amine exchange reactant, wherein the reactant labels parylation sites of the proteins.
12/18/14
20140370548
 Antibodies immunoreactive with heregulin-coupled her3 patent thumbnailnew patent Antibodies immunoreactive with heregulin-coupled her3
Recombinant materials and methods for producing antibodies that specifically bind heregulin-coupled her3, at a site distinct from the heregulin binding site, are described. These antibodies are particularly useful in treating cancer that expresses her3..
12/18/14
20140370547
 Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides patent thumbnailnew patent Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
Herein is reported an expression vector comprising—an antibody light chain expression cassette,—an antibody heavy chain expression cassette, and—a selection marker expression cassette, wherein the expression cassettes are arranged unidirectional, and wherein the expression cassettes are arranged in the 5′ to 3′ sequence of antibody heavy chain expression cassette, antibody light chain expression cassette and selection marker expression cassette. Further are reported herein methods for the generation of antibody producing cells and the use of these cells for the recombinant production of antibodies..
12/18/14
20140370526
 Detecting inclusion body myositis patent thumbnailnew patent Detecting inclusion body myositis
Methods, devices, kits and systems for diagnosing inclusion body myositis (ibm) are provided. Methods, devices, kits and systems involves detecting the presence and/or level of autoantibodies that are reactive against at least a ˜43 kilodalton (kda) protein or ˜43 kda protein band from a muscle lysate or a mammalian cell lysate, or autoantibodies that are reactive against a cytosolic 5′-nucleotidase 1a protein (nt5c1a), or a cytosolic 5′-nucleotidase 1b protein (nt5c1b), or a nt5c1b isoform thereof, or a peptide fragment thereof, an isolated peptide thereof or a fusion protein comprising an isolated peptide of nt5c1a or nt5c1b.
12/18/14
20140370525
 Alpha-hemoglobin stabilizing protein antibodies and methods of use thereof patent thumbnailnew patent Alpha-hemoglobin stabilizing protein antibodies and methods of use thereof
Methods for detecting and/or imaging erythrocyte precursor cells are provided.. .
12/18/14
20140370037
 Dll3 modulators and methods of use patent thumbnailnew patent Dll3 modulators and methods of use
Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.. .
12/18/14
20140370035
new patent Methods of reducing immunogenicity against factor viii in individuals undergoing factor viii therapy
The present disclosure provides methods of administering chimeric and hybrid factor viii (fviii) polypeptides comprising fviii and fc to subjects at risk of developing inhibitory fviii immune responses, including anti-fviii antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to fviii.
12/18/14
20140370032
new patent Multi-strain-reactive antibodies for therapy and diagnosis of influenza
The invention relates to a method for isolating a polypeptide reactive to influenza a hemagglutinin, comprising the steps of preparing a library of nucleic acid sequences, wherein each member of said library is attached to a polypeptide sequence encoded thereby, selecting members of said library by contacting the members with a panning antigen, wherein the panning antigen comprises a hemagglutinin stem region polypeptide sequence, subsequently removing members unreactive to the panning antigen, and selecting a member of said library by determining its binding to at least 5 influenza a hemagglutinin subtypes of subtype group 1 and 2. The invention further relates to polypeptides, particularly antibodies, obtainable by this method, that neutralize at least five influenza a subtypes of subtype group 1 and 2, to vaccines and uses thereof..
12/18/14
20140370031
new patent Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins
A method of producing a metalloprotein inhibitor, the method comprising generating antibodies directed at a composition including a metal ion-bound chelator, wherein the composition is selected having structural and electronic properties similar to a functional domain of the metalloprotein, thereby producing the metalloprotein inhibitor.. .
12/18/14
20140370030
new patent Antibodies anti-spla2-x and uses thereof
The present invention relates to isolated antibodies against human spla2-x and uses thereof.. .
12/18/14
20140370026
new patent Cytomegalovirus surface protein complex for use in vaccines and as a drug target
Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (cmv) are disclosed. Subunit vaccines comprising a human cmv protein complex comprising pul128 or pul130, and nucleic acid vaccines comprising at least one nucleic acid encoding a cmv protein complex comprising pul128 or pul130 are described.
12/18/14
20140370023
new patent Erg monoclonal antibodies
Monoclonal antibodies, or antigen-binding fragments thereof, that bind to erg, and more specifically, to an epitope formed by amino acids 42-66 of erg3 are disclosed. The monoclonal antibodies can be non-human antibodies (e.g., rabbit or mouse) or humanized monoclonal antibodies having the cdr regions derived from those non-human antibodies.
12/18/14
20140370022
new patent Antibodies cross-reactive to human and mouse c-met and uses thereof
The antibody of the invention has high specificity to human c-met and is cross-reactive to mouse c-met. The antibody or its antigen-binding fragment of the invention is capable of specifically binding to human c-met as well as mouse c-met, more accurate preclinical results can be confirmed in the efficacy evaluation using mouse tumor models.
12/18/14
20140370021
new patent Optimized fc variants and methods for their generation
The present invention relates to optimized fc variants, methods for their generation, and antibodies and fc fusions comprising optimized fc variants.. .
12/18/14
20140370019
new patent Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use
The present invention relates to bispecific antibodies comprising at least one antigen binding site specific for dr5 and at least one antigen binding site specific for fap, antibodies specific for dr5, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.. .
12/18/14
20140370018
new patent Multi-specific antigen-binding molecules and uses thereof
Various bispecific antibodies that specifically bind to both blood coagulation factor ix/activated blood coagulation factor ix and blood coagulation factor x and functionally substitute for the cofactor function of blood coagulation factor viii, that is, the function to promote activation of blood coagulation factor x by activated blood coagulation factor ix, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor viii were successfully discovered..
12/18/14
20140370015
new patent Use of il-20 antagonists for alleviating spinal cord injury
Alleviating neural injury, such as spinal cord injury, in a subject (e.g., a human subject) in need of the treatment using an il-20 antagonist, which can be an antibody that blocks a signaling pathway mediated by il-20. Such antibodies include anti-il-20 antibodies and anti-il-20r antibodies that specifically block the il-20 signaling pathway..
12/18/14
20140370014
new patent Use of il-20 antagonists for alleviating obesity
Alleviating obesity in a subject (e.g., a human subject) having, being suspected of having, or at risk for obesity using an il-20 antagonist, which can be an antibody that blocks a signaling pathway mediated by il-20. Such antibodies include anti-il-20 antibodies and anti-il-20r antibodies that specifically block the il-20 signaling pathway..
12/18/14
20140370013
new patent Novel heterodimeric proteins
The invention provides novel heterodimeric proteins including heterodimeric antibodies.. .
12/18/14
20140370010
new patent Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3
The invention provides methods and compositions comprising anti-epha3 antibodies for the treatment of myeloproliferative disorders.. .
12/18/14
20140370008
new patent Thrombin-binding antibody molecules and uses thereof
This invention relates to isolated antibodies which recognise the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin..
12/18/14
20140370003
new patent Process for concentration of antibodies and therapeutic products thereof
The present disclosure provides a process for concentrating proteins including an ultrafiltering, a diafiltering, and a second ultrafiltering sequence, at elevated temperatures, such as above about 30° c. The disclosure also includes a process for preparing highly concentrated antibody compositions, and highly concentrated antibody products..
12/18/14
20140370001
new patent Ige antibodies for the inhibition of tumor metastasis
The present invention provides novel ige antibodies useful for inhibiting or preventing metastatic cancer. Also provided are methods to inhibit tumor metastasis by modulating the activity of at least one non-tumor cell, treating a patient to inhibit or prevent tumor metastases of a primary solid tumor, treating metastatic carcinoma, reducing metastasis of carcinoma cells, and reducing the growth kinetics of a primary solid tumor or a metastasized cell or tumor..
12/18/14
20140369985
new patent Removal of tumor cells from intraoperative autologous blood salvage
The invention relates to a method performed ex vivo for removal of tumor cells from intraoperatively collected blood salvage, to antibodies and scaffold proteins which mimic antibodies for use in said ex vivo method, to the use of said ex vivo method for removal of tumor cells from intraoperatively collected blood salvage followed by reintroducing the so obtained purified blood salvage or of concentrates of erythrocytes purified by said method to a patient from whom said intra-operatively collected blood was obtained, as well as to blood salvage or a concentrate of erythrocytes, both obtainable by said method for reinfusion to said patient.. .
12/18/14
20140369940
new patent Anti-alpha synuclein binding molecules
Provided are anti-human α-synuclein-specific binding molecules, e.g., antibodies or antigen-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human α-synuclein binding molecules which bind to specific n-terminal and c-terminal epitopes on human α-synuclein.
12/18/14
20140369927
new patent Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
Disclosed herein are compositions and methods of use comprising combinations of anti-cd22 antibodies with a therapeutic agent. The therapeutic agent may be attached to the anti-cd22 antibody or may be separately administered, either before, simultaneously with or after the anti-cd22 antibody.
12/18/14
20140369926
new patent Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
The present invention provides for recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens, along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to the nucleic acids, and uses for these antibodies, nucleic acids and amino acids.. .
12/18/14
20140369925
new patent Antibodies
The present invention provides antibodies which bind to cxc chemokine receptor 4 (cxcr4) and which do not induce significant apoptosis of cxcr4 expressing cells. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields..
12/18/14
20140369924
new patent Synergistic anti-cd47 therapy for hematologic cancers
Methods are provided for treatment of hematologic cancers, particularly lymphomas and leukemias, including without limitation myelogenous and lymphocytic leukemias. A combination of antibodies specific for cd47; and specific for a cancer associated cell surface marker are administered to the patient, and provide for a synergistic decrease in cancer cell burden.
12/11/14
20140364593
Dll3 modulators and methods of use
Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.. .
12/11/14
20140364590
Dll3 modulators and methods of use
Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.. .
12/11/14
20140364332
Peptides and methods for the detection of lyme disease antibodies
The invention provides compositions (e.g., peptide compositions) useful for the detection of antibodies that bind to borrelia antigens. The peptide compositions comprise polypeptide sequences comprising variants in the ir6 domain of the borrelia vlse protein.
12/11/14
20140364326
Combinatorial biomarkers for clinical applications in lung cancer patient management
The present invention relates to compositions and methods for detecting, managing or monitoring cancer. The invention also relates to antibodies specific for cancer markers, compositions and chips containing the same, as well as their uses for cancer detection, managing, monitoring, imaging or treatment, as well as for drug development.
12/11/14
20140363887
Dll3 modulators and methods of use
Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.. .
12/11/14
20140363829
Method for increasing specificity of diagnostic tests for autoimmune diseases
Provided is a method for increasing the specificity of an antibody-based test to help in the diagnosis of autoimmune diseases by contacting a subject's sample with a blocking antigen prior interfering antibody present in the sample. More specifically, a method for increasing specificity of an antibody-based autoimmune disease assay comprising the steps of providing a sample from a subject, contacting the sample with a dfs70 derived antigen, reacting the sample with an autoimmune disease target and detecting antibodies to the autoimmune disease target is disclosed..
12/11/14
20140363826
Dll3 modulators and methods of use
Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.. .
12/11/14
20140363813
Sperm-specific cation channel, catsper2, and uses therefor
Nucleic acid and protein sequences relating to a cation channel which is sperm-specific (catsper2) are disclosed. The catsper2 protein is shown to be specifically expressed in sperm.
12/11/14
20140363500
Use of an antibody and a particulate immunomodulator
The current invention is directed to particulate or vesicular immunomodulators, like e.g. Cytokines, for use in combination therapy with antibodies for treatments of a range of conditions and diseases, in particular cancer, as well as methods, compositions, and kits thereof..
12/11/14
20140363494
Pharmaceutical compositions for the treatment of tumors expressing egfr and gm3 n-glycolyl ganglioside (neugcgm3)
The present invention relates to pharmaceutical compositions for the treatment of malignant tumors. Particularly those tumors that express egfr and gm3 n-glycolyl ganglioside targets to enhance the therapeutic effect produced by separated therapies against these targets.
12/11/14
20140363459
Synthetic capsid proteins and uses thereof
The present invention relates to synthetic proteins and the uses thereof. More particularly, the invention relates to synthetic circovirus type capsid proteins with improved properties.
12/11/14
20140363455
Dll3 modulators and methods of use
Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.. .
12/11/14
20140363450
Oxidized cardiolipin as a novel pro-inflammatory factor
Low levels of antibodies reactive with oxidised cardiolipin (oxcl) in mammals are related to an increased risk of developing cardiovascular diseases, auto-immune diseases or inflammatory conditions. High levels can have a protective function and in general there is a negative association between manifestations of these conditions and antibodies against oxcl.
12/11/14
20140363447
Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies
Antibodies and fragments thereof have high affinity for human α-synuclein protofibrils and low binding of α-synuclein monomers, wherein the antibodies or fragments have specified complementarity determining region (cdr) sequences. Compositions comprise such an antibody or fragment and methods of detecting α-synuclein protofibrils use such an antibody or fragment.
12/11/14
20140363446
Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against vsig1, ildr1, loc253012, ai216611, c1orf32 or fxyd3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages.
12/11/14
20140363444
Anti-il-23 antibodies
The present invention relates to anti-il-23p19 binding compounds, in particular new humanized anti-il-23p19 antibodies and therapeutic and diagnostic methods and compositions for using the same.. .
12/11/14
20140363442
Therapeutic cd47 antibodies
Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to cd47 of multiple mammalian species, block the binding of sirpalpha and tsp1 to cd47, promote phagocytosis of susceptible cancer cells, and reverse tsp1 inhibition of nitric oxide signaling, as well as monoclonal antibodies and antigen binding fragments thereof that compete with the former for binding to cd47 and that exhibit similar biological activities. Also provided are combinations of any of the foregoing.
12/11/14
20140363441
Compositions and methods for the therapy and diagnosis of influenza
The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection..
12/11/14
20140363440
Antibodies and their uses for diagnosis and treatment of cytomegalovirus infection and associated diseases
Anti cmv antibodies are provided. Thus an antibody of the present invention comprises an antigen recognition domain capable of binding an mhc molecule being complexed with a cytomegalovirus (cmv) pp65 or pp64 peptide, wherein the antibody does not bind said mhc molecule in an absence of said complexed peptide, and wherein the antibody does not bind said peptide in an absence of said mhc molecule.
12/11/14
20140363439
Anti-lrp6 antibodies
The invention provides anti-lrp6 antibodies and methods of using the same. A particular aspect of the invention provides for bispecific anti-lrp6 antibodies that inhibit signaling by multiple wnt isoforms..
12/11/14
20140363438
Neuregulin antibodies and uses thereof
The invention provides anti-neuregulin1 antibodies and methods of using the antibodies in treating diseases or disorders, such as cancer. In a particular embodiment, the anti-neuregulin1 antibodies bind to both neuregulin1α and neuregulin 1β isoforms..
12/11/14
20140363433
Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
In one aspect, the invention provides a method of making a bioactive peptide-bearing antibody, or fragment thereof, comprising (a) engrafting the amino acid sequence of at least one bioactive peptide of interest into (i) at least one of cdr-h1, cdr-h2 or cdr-h3 of a heavy chain variable region comprising one or more chicken framework regions and/or (ii) at least one of cdr-l1, cdr-l2 or cdr-l3 of the light chain variable region comprising one or more chicken framework regions, and (b) determining whether the antibody has substantially the same biological activity as the bioactive peptide.. .
12/11/14
20140363432
Vascular endothelial cell growth factor antagonists and uses thereof
The present invention provides vascular endothelial cell growth factor (vegf) antagonists and methods of using vegf antagonists. Vegf antagonists contemplated by the invention include vegf antibodies and vegf receptor fusion proteins.
12/11/14
20140363430
Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
The invention relates generally to activatable antibodies that include a masking moiety (mm), a cleavable moiety (cm), and an antibody (ab) that specifically binds to interleukin-6 receptor (il-6r), and to methods of making and using these anti-il-6r activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.. .
12/11/14
20140363429
Binding molecules specific for her3 and uses thereof
The present invention relates to antibodies and antigen binding fragments thereof that bind the extracellular domain of the her3 receptor and inhibit various her3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life.
12/11/14
20140363427
Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
Provided herein are antibodies or antigen-binding fragments thereof that immunospecifically bind to the fusion (f) protein of respiratory syncytial virus (rsv). Also provided are methods for of prevention, treatment and diagnosis of viral infection and/or the treatment of one more symptoms of rsv-mediated disease.
12/11/14
20140363426
Heterodimeric proteins
In one aspect, the present invention provides heterodimeric antibodies comprising a first monomer comprising a first heavy chain constant domain comprising a first variant fc domain and a first antigen binding domain and a second monomer comprising a second heavy chain constant domain comprising a second variant fc domain and a second antigen binding domain. In an additional aspect the heterodimeric antibody comprises a first monomer comprising a heavy chain comprising a first fc domain and a single chain fv region (scfv) that binds a first antigen, wherein the scfv comprises a charged scfv linker.
12/11/14
20140363424
Use of chimeric anti-cd20 antibody as in vitro or in vivo purging agent in patients receiving bmt or pbsc transplant
The use of anti-cd20 antibodies as in vivo purging agents for patients receiving bone marrow or peripheral blood stem cell transplant during treatment of b-cell-related diseases, e.g., b-cell lymphomas or leukemias, is disclosed. Such purging may enhance engraftment and/or prevent disease relapse in such patients..
12/11/14
20140363422
Method of providing monoclonal auto-antibodies with desired specificity
Provided are novel binding molecules of human origin, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize antigens such as native endogenous proteins associated with, e.g., immune response, autoimmune disorders, inflammatory diseases, metabolic disorders, vascular function, neurodegenerative diseases or tumors. More particularly, a human auto-immunosome and corresponding monoclonal antibody reservoir are provided.
12/11/14
20140363414
Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
A naturally occurring or recombinant protein, especially a mutein of porcine urate oxidase (uricase), that is essentially free of large aggregates can be rendered substantially non-immunogenic by conjugation with a sufficiently small number of strands of polymer such that the bioactivity of the protein is essentially retained in the conjugate. Such conjugates are unusually well suited for treatment of chronic conditions because they are less likely to induce the formation of antibodies and/or accelerated clearance than are similar conjugates prepared from protein preparations containing traces of large aggregates..
12/04/14
20140359902
Expression of secretory iga antibodies in duckweed
Secretory iga antibodies can be made by expression in a stably-transformed duckweed.. .
12/04/14
20140359797
Chimaeric surrogate light chains (slc) comprising human vpreb
The present invention relates inter alia to improvements in the production of chimaeric antibodies in non-human transgenic vertebrates such as mice and rats bearing one or more chimaeric antibody transgenes. In particular, the invention provides for improved non-human vertebrates and cells in which vpreb has been species-matched with the variable region of the chimaeric antibodies.
12/04/14
20140358066
Methods and devices for stimulating an immune response using nanosecond pulsed electric fields
Nanosecond pulsed electric field (nspef) treatments of a tumor are used to cause the tumor to express calreticulin and stimulate an immune response against the tumor and other tumors in a subject. An immune response biomarker can be measured, and further nspef treatments can be performed if needed to stimulate or further stimulate the immune response.
12/04/14
20140357844
Antibodies specific for trop-2 and their uses
The present invention provides antibodies that specifically bind to trophoblast cell-surface antigen-2 (trop-2). The invention further provides antibody conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies.
12/04/14
20140357522
Simultaneous assay of target and target-drug binding
Whole cell, simultaneous target and drug-target assay using differentially labeled antibodies and flow cytometry. First antibody binds to total target and second antibody binds to the drug binding site of the target, thus drug binding will competitively inhibit the second antibody allowing for a competitive inhibition assay of drug-target binding.
12/04/14
20140357520
Mycobacterium tuberculosis specific peptides for detection of infection or immunization in non-human primates
The present invention relates to novel peptides that may be used in whole or in combination for the detection of mycobacterium tuberculosis infection. In particular, the present invention relates to compositions and methods involving detection of antibodies contained in the blood of non-human primates that arise from an infection from m.
12/04/14
20140357519
Methods of screening monoclonal antibody populations
The present invention concerns methods and compositions for screening primary hybridoma cultures to generate monoclonal antibodies that are useful in a variety of methods, including for in situ cellular imaging by immunocytochemical assays or in vivo applications, for example. Embodiments of the methods concern the use of automated high-throughput immunofluorescence (for example) to identify subcellular in vivo patterns that are expected based on the antigen or that may be unforeseen..
12/04/14
20140357500
Single cell bar-coding for antibody discovery
Provided herein are methods and composition for immune repertoire sequencing and single cell barcoding for heavy and igl pairing if antibodies.. .


Popular terms: [SEARCH]

Antibodies topics: Antibodies, Recombinant, Nucleic Acid, Nucleic Acids, Polypeptide, Therapeutics, Immunoglobulin, Immunoglobulins, Monoclonal, Radiation Therapy, Desmoplastic, Hypertension, Hypertensive, Immunotherapy, Photodynamic Therapy

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Antibodies for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Antibodies with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         



Key IP Translations - Patent Translations



0.3784

3477

449991 - 0 - 75